Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.61 |
| ▸ | USP2 | O75604 | 7/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.61 |
| ▸ | TP53 | P04637 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.40 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18357559 | 0.90 | TSHR (0.51) | TSHRCYP2D6USP2ALDH1A1CYP1A2 | |
| SCHEMBL21393004 | 0.89 | CYP2D6 (0.55) | TSHRCYP2D6USP2ALDH1A1CYP1A2 | |
| SCHEMBL1779898 | 0.85 | CYP2D6 (0.65) | TSHRCYP2D6USP2ALDH1A1CYP1A2 | |
| SCHEMBL18357436 | 0.84 | TP53 (0.47) | TSHRCYP2D6USP2ALDH1A1CYP1A2 | |
| SCHEMBL22914774 | 0.79 | KCNH2 (0.54) | TSHRCYP2D6USP2ALDH1A1CYP1A2 | |
| SCHEMBL2819190 | 0.79 | USP2 (0.53) | TSHRCYP2D6USP2ALDH1A1CYP1A2 | |
| SCHEMBL22914757 | 0.79 | TSHR (0.50) | TSHRCYP2D6USP2ALDH1A1CYP1A2 | |
| SCHEMBL19139673 | 0.78 | TSHR (1.00) | TSHRCYP2D6USP2ALDH1A1CYP1A2 | |
| SCHEMBL22922220 | 0.78 | KCNH2 (0.60) | TSHRCYP2D6USP2ALDH1A1CYP1A2 | |
| SCHEMBL22914820 | 0.77 | KDM4E (0.47) | TSHRTP53KCNH2KDM4ECHRNA10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118666853-A | N-methyl N- (6- (methoxy) pyridazin-3-yl) amine derivatives for the treatment of inflammatory airway diseases or fibrotic diseases | 勃林格殷格翰国际有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-114206876-B | N-methyl, N- (6- (methoxy) pyridazin-3-yl) amine derivatives as modulators of Autotaxin (ATX) for the treatment of inflammatory airway diseases or fibrotic diseases | 勃林格殷格翰国际有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-114206871-B | 1- (6- (methoxy) pyridazin-3-yl) cyclopropane-1-carboxamide derivatives as modulators of Autotaxin (ATX) for the treatment of inflammatory airway diseases | 勃林格殷格翰国际有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11918575-B2 | PZA and cytochrome Bc1 inhibitor combination treatment | Janssen Sciences Ireland Unlimited Company (IE) | 2024-03-05 | — | — | US | disclosed |
| US-11918575-B2 | PZA and cytochrome Bc1 inhibitor combination treatment | Janssen Sciences Ireland Unlimited Company (IE) | 2024-03-05 | — | — | US | disclosed |
| CN-114206871-A | 1- (6- (methoxy) pyridazin-3-yl) cyclopropane-1-carboxamide derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway diseases | 勃林格殷格翰国际有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114206876-A | N-methyl, N- (6- (methoxy) pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway diseases or fibrotic diseases | 勃林格殷格翰国际有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-11224596-B2 | PZA and cytochrome bc1 inhibitor combination treatment | Janssen Sciences Ireland Unlimited Company (IE) | 2022-01-18 | — | — | US | disclosed |
| US-20210024495-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11224596-B2 | PZA and cytochrome bc1 inhibitor combination treatment | CYC1, MT-ND1, MT-CO1 | TSHR 4004/4885CYP2D6 185/4885USP2 2120/4885 |
| US-20210024495-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | TSHR 868/4885CYP2D6 3729/4885USP2 1421/4885 |
| US-11918575-B2 | PZA and cytochrome Bc1 inhibitor combination treatment | CYC1, MT-ND1, MT-CO1 | TSHR 4004/4885CYP2D6 185/4885USP2 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.